We chose to test glioblastoma-derived EVs instead of plasma from these patients to detect membrane-bound FX for clotting because glioblastoma cells survive poorly in the systemic circulation [25], but patients with the cancer often develop a systemic prothrombotic state [21], which is likely triggered by circulating mediators. This evidence concerns the gene F10 and glioblastoma.